Sirius Therapeutics is developing siRNA therapeutics targeting cardiometabolic disorders and next-generation RNA delivery technologies. The company has three clinical-stage programs and a deep preclinical pipeline. Its lead candidate, SRSD107, is a long‑acting anticoagulant poised to begin Phase 2 clinical development in Europe, with an application submitted to the EMA. SRSD216 has begun Phase 1 studies after receiving U.S. FDA and China NMPA approvals for trials in hyperlipoproteinemia in patients with atherosclerotic cardiovascular disease. SRSD101 is undergoing Phase 1 clinical trials in China. Sirius plans to use the new financing to advance clinical programs and expand its pipeline globally.

Total raised

$50M

Funding rounds

1

Latest round

Series B

Latest activity

May 2025